According to the documents, under the pathological condition of RA which is accompanied by an increased level of inflammatory mediators, IL‐6 can mediate thrombo‐inflammatory responses associated with angiotensin II, a critical determinant that is responsible for both thromboinflammation and hypertension, so targeting IL‐6 signalling pathway could help manage thrombo‐inflammatory diseases and hypertension.43 The gene discussed is IL6; the disease is rheumatoid arthritis.